NCT01547260 - Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2014

Study Completion Date

November 30, 2014

Conditions

Pancreatic Carcinoma MetastaticPancreatic Ductal Adenocarcinoma

Interventions

DRUG

Gemzar

Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).

DRUG

Revlimid

Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.

Trial Locations (1)

171 76

Karolinska University Hospital, Stockholm